NICE clears Boehringer's Pradaxa in final appraisal determination
This article was originally published in Scrip
Executive Summary
NICEhas recommended Boehringer Ingelheim's Pradaxa (dabigatran etexilate) for the primary prevention of venous thromboembolic events in adults who have undergone elective total hip replacement surgery or elective total knee replacement surgery. It was approved in the EU in March.